Skip to content

US · GRCE · BIOTECHNOLOGY

Grace Therapeutics, Inc. (GRCE) intrinsic value and stock valuation

$1.71as of 2026-11-21 · Mkt cap 34.83M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Grace Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values GRCE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from GRCE’s statements →

Grace Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Princeton, NJ 08540 gracetx.com

How the business is doing

Fiscal 2012–2026, USD

Revenue
$0.00
20122026
Net income
-$-7.79M
20122026
Free cash flow
-$-8.87M
20122026
Total equity
$63.9M-1.8% 5y CAGRd
20122026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2026, USD
20262025202420232022
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-11.08M-$-23.75M-$-17.44M-$-70.54M-$-19.48M
Net income-$-7.79M-$-13.63M-$-17.44M-$-57.39M-$-12.27M
EPSd-$-471.84K-$-1.13M-$-1.83M-$-7.71M-$-2M
Operating cash flow-$-8.87M-$-14.9M-$-12.33M-$-15.91M-$-17.23M
Capital expenditure$0.00$0.00-$-20K-$-20K$0.00
Free cash flow-$-8.87M-$-14.9M-$-12.36M-$-15.93M-$-17.23M
Total assets$66.7M$72M$73.3M$79.1M$128.6M
Total debt$0.00$0.00$0.00$480K$290K
Net debt-$-16.98M-$-22.13M-$-23M-$-27.39M-$-30.04M
Total equity$63.9M$66.6M$61.7M$68M$108.3M
Cash and short-term investments$17M$22.1M$23M$27.9M$43.7M
Income statement
20262025202420232022
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$2.4M$13.5M$6.35M$13.5M$6.95M
Selling, general and administrative expenses$8.66M$10.2M$9.02M$11.1M$12.2M
Other expenses$10K$10K$2.07M$46M$310K
Operating expenses$11.1M$23.8M$17.4M$70.5M$19.5M
Cost and expenses$11.1M$23.8M$17.4M$70.5M$19.5M
Interest income$690K$710K$910K$250K$80K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$10K$10K$50K$170K$0.00
Ebitda-$-11.07M-$-23.74M-$-15.37M-$-24.51M-$-19.17M
Operating income-$-11.08M-$-23.75M-$-17.44M-$-70.54M-$-19.48M
Total other income/expenses, net$1.58M$5.57M-$-2.49M$250K$6.4M
Income before tax-$-9.49M-$-18.18M-$-19.93M-$-70.29M-$-13.08M
Income tax expense-$-1.7M-$-4.56M-$-2.49M-$-12.91M-$-810K
Net income-$-7.79M-$-13.63M-$-17.44M-$-57.39M-$-12.27M
Weighted average shares outstanding$16.5M$12.1M$9.53M$7.44M$6.14M
Weighted average diluted shares outstanding$16.5M$12.1M$9.53M$7.44M$6.14M
Balance sheet
20262025202420232022
Cash and short-term investments$17M$22.1M$23M$27.9M$43.7M
Net receivables$20K$130K$720K$800K$550K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$17.4M$22.7M$24M$29.3M$45.5M
Property, plant and equipment, net$10K$10K$20K$570K$320K
Goodwill and intangible assets$49.3M$49.3M$49.3M$49.3M$82.8M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$49.3M$49.3M$49.3M$49.8M$83.1M
Total assets$66.7M$72M$73.3M$79.1M$128.6M
Accounts payable$700K$600K$1.01M$1.24M$3.16M
Short-term debt$0.00$0.00$0.00$70K$100K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.15M$1.93M$1.68M$3.41M$3.26M
Long-term debt$0.00$0.00$0.00$410K$190K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$610K$3.45M$9.87M$7.76M$17.1M
Capital lease obligations$0.00$0.00$0.00$410K$190K
Total liabilities$2.76M$5.38M$11.6M$11.2M$20.4M
Common stock$0.00$0.00$261M$258.3M$258M
Retained earnings-$-228.48M-$-220.69M-$-211.12M-$-198.27M-$-155.84M
Accumulated other comprehensive income (loss)-$-6.04M-$-6.04M-$-6.04M-$-6.04M-$-6.04M
Total equity$63.9M$66.6M$61.7M$68M$108.3M
Total investments$0.00$0.00$0.00$10K$13.3M
Total debt$0.00$0.00$0.00$480K$290K
Net debt-$-16.98M-$-22.13M-$-23M-$-27.39M-$-30.04M
Cash flow statement
20262025202420232022
Net income-$-7.79M-$-9.57M-$-12.85M-$-42.43M-$-9.82M
Depreciation and amortization$10K$10K$10K$120K$0.00
Stock-based compensation$800K$730K$910K$1.81M$1.34M
Change in working capital$720K$340K-$-1.28M$180K-$-2.79M
Accounts receivable$110K$600K$80K-$-300K-$-20K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$540K$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-8.87M-$-14.9M-$-12.33M-$-15.91M-$-17.23M
Investments in property, plant and equipment$0.00$0.00-$-20K-$-20K$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$100K$13.2M-$-3.52M
Common stock issued$3.71M$15M$7.5M$300K$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$3.71M$14M$7.36M$300K$0.00
Net change in cash-$-5.16M-$-870K-$-4.87M-$-2.46M-$-20.6M
Cash at end of period$17M$22.1M$23M$27.9M$30.3M
Operating cash flow-$-8.87M-$-14.9M-$-12.33M-$-15.91M-$-17.23M
Capital expenditure$0.00$0.00-$-20K-$-20K$0.00
Free cash flow-$-8.87M-$-14.9M-$-12.36M-$-15.93M-$-17.23M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Grace Therapeutics, Inc.

        Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.

        CEO
        Prashant Kohli
        Employees
        5
        Beta
        0.37

        Explore

        Frequently asked questions

        What is the intrinsic value of Grace Therapeutics, Inc. (GRCE)?

        InvestorsCraft does not currently publish an intrinsic value for GRCE. How the IC value is calculated.

        Is GRCE undervalued?

        InvestorsCraft does not publish an undervaluation signal for GRCE at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.